Fig. 3.

Overexpression of 22.5 kDa FGF2 isoform induces T47D-YA cell proliferation, tumor growth, endocrine resistance, and 22.5 metastatic dissemination. a Baseline cell proliferation of T47D-YA-p6NST50, T47D-YA-18, and T47D-YA-22.5 cells was measured by total cell counting. b In vivo growth of T47D-YA-p6NST50, T47D-YA-18, and T47D-YA-22.5 cells (NSG mice, N = 4/group). Tumor size, tumor weight, and metastatic lung foci at the end of the experiment (day 56 after cell injection). The asterisks indicate the statistical significance of experimental groups vs. T47D-YA-p6NST50. c Cell proliferation of T47D-YA-p6NST50, T47D-YA-18, and T47D-YA-22.5 cells was measured by total cell counting. Cells were starved for 24 h in 1% chFCS and then treated during 5 days with 10⁻⁷ M of mifepristone (MFP; left), telapristone acetate (TLP; center), or tamoxifen (TAM; right). The asterisks indicate the statistical significance of treated cells (+) vs. untreated cells (−). d In vivo growth of T47D-YA-p6NST50, T47D-YA-18, and T47D-YA-22.5 cells (NSG mice, N = 4/group). The data shown is representative of two independent experiments. Inset, tumor weight at the end of each experiment